Bita Taghizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bita Taghizadeh has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Laleh Ghavami
3 shared publicationsAlireza Nikoofar
Department of Radiobiology, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications- Bahram Goliaei
Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
2 shared publications Aida Alizamir
1 shared publicationAli Nokhodchi
1 shared publicationFarshad Mirzavi
1 shared publication
Latest Publications
- Open Access
- 5 November 2025
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 18 (3) , 643-661
Puerarin as a multifaceted anticancer agent: Mechanisms, targets, and therapeutic potential across multiple cancers
- 5 November 2025
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 18 (3) , 643-661
Open AccessPuerarin as a multifaceted anticancer agent: Mechanisms, targets, and therapeutic potential across multiple cancers
- 1 December 2014
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 775-776, 1-6
Effects of barley β-glucan on radiation damage in the human hepatoma cell line HepG2
- 1 December 2014
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 775-776, 1-6
Effects of barley β-glucan on radiation damage in the human hepatoma cell line HepG2
- 17 February 2014
- Published by Taylor & Francis in Drug Delivery
- Vol. 22 (2) , 145-155
Classification of stimuli–responsive polymers as anticancer drug delivery systems
Although several anticancer drugs have been introduced as chemotherapeutic agents, the effective treatment of cancer remains a challenge. Major limitations in the application of anticancer drugs include their nonspecificity, wide biodistribution, short half-life, low concentration in tumor tissue and systemic toxicity. Drug delivery to the tumor site has become feasible in recent years, and recent advances in the development of new drug delivery systems for controlled drug release in tumor tissues with reduced side effects show great promise. In this field, the use of biodegradable polymers as drug carriers has attracted the most attention. However, drug release is still difficult to control even when a polymeric drug carrier is used. The design of pharmaceutical polymers that respond to external stimuli (known as stimuli-responsive polymers) such as temperature, pH, electric or magnetic field, enzymes, ultrasound waves, etc. appears to be a successful approach. In these systems, drug release is triggered by different stimuli. The purpose of this review is to summarize different types of polymeric drug carriers and stimuli, in addition to the combination use of stimuli in order to achieve a better controlled drug release, and it discusses their potential strengths and applications. A survey of the recent literature on various stimuli-responsive drug delivery systems is also provided and perspectives on possible future developments in controlled drug release at tumor site have been discussed.
- 17 February 2014
- Published by Taylor & Francis in Drug Delivery
- Vol. 22 (2) , 145-155
Classification of stimuli–responsive polymers as anticancer drug delivery systems
Although several anticancer drugs have been introduced as chemotherapeutic agents, the effective treatment of cancer remains a challenge. Major limitations in the application of anticancer drugs include their nonspecificity, wide biodistribution, short half-life, low concentration in tumor tissue and systemic toxicity. Drug delivery to the tumor site has become feasible in recent years, and recent advances in the development of new drug delivery systems for controlled drug release in tumor tissues with reduced side effects show great promise. In this field, the use of biodegradable polymers as drug carriers has attracted the most attention. However, drug release is still difficult to control even when a polymeric drug carrier is used. The design of pharmaceutical polymers that respond to external stimuli (known as stimuli-responsive polymers) such as temperature, pH, electric or magnetic field, enzymes, ultrasound waves, etc. appears to be a successful approach. In these systems, drug release is triggered by different stimuli. The purpose of this review is to summarize different types of polymeric drug carriers and stimuli, in addition to the combination use of stimuli in order to achieve a better controlled drug release, and it discusses their potential strengths and applications. A survey of the recent literature on various stimuli-responsive drug delivery systems is also provided and perspectives on possible future developments in controlled drug release at tumor site have been discussed.
- 7 September 2013
- Published by Springer Nature in Breast Cancer
- Vol. 22 (4) , 382-390
Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines
Background Breast cancer is the most common cause of cancer death among women worldwide, and diet plays an important role in its prevention and progression. Radiotherapy has a limited but important role in the management of nearly every stage of breast cancer. We studied whether equol, the major metabolite of the soybean isoflavone daidzein, could enhance radiosensitivity in two human breast cancer cell lines (T47D and MDA-MB-231). Methods MTT assay was used to examine equol’s effect on cell viability. Sensitivity of cells to equol, radiation and a combination of both was determined by colonogenic assays. Induction of apoptosis by equol, radiation and the combination of both was also determined by acridine orange/ethidium bromide double staining fluorescence microscopy. DNA strand breaks were assessed by Comet assay. Result MTT assay showed that equol (0.1–350 μM) inhibited MDA-MB-231 and T47D cell growth in a time- and dose-dependent manner. Treatment of cells with equol for 72 h (MDA-MB-231) and 24 h (T47D) was found to inhibit cell growth with IC50 values of 252 μM and 228 μM, respectively. Furthermore, pretreatment of cells with 50 μM equol for 72 h (MDA-MB-231) and 24 h (T47D) sensitized the cells to irradiation. Equol was also found to enhance radiation-induced apoptosis. Comet assay results showed that the radiosensitizing effect of equol was accompanied by increased radiation-induced DNA damages. Conclusions These results suggest for the first time that equol can be considered as a radiosensitizing agent and its effects may be due to increasing cell death following irradiation, increasing the remaining radiation-induced DNA damage and thus reducing the surviving fraction of irradiated cells.
- 7 September 2013
- Published by Springer Nature in Breast Cancer
- Vol. 22 (4) , 382-390
Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines
Background Breast cancer is the most common cause of cancer death among women worldwide, and diet plays an important role in its prevention and progression. Radiotherapy has a limited but important role in the management of nearly every stage of breast cancer. We studied whether equol, the major metabolite of the soybean isoflavone daidzein, could enhance radiosensitivity in two human breast cancer cell lines (T47D and MDA-MB-231). Methods MTT assay was used to examine equol’s effect on cell viability. Sensitivity of cells to equol, radiation and a combination of both was determined by colonogenic assays. Induction of apoptosis by equol, radiation and the combination of both was also determined by acridine orange/ethidium bromide double staining fluorescence microscopy. DNA strand breaks were assessed by Comet assay. Result MTT assay showed that equol (0.1–350 μM) inhibited MDA-MB-231 and T47D cell growth in a time- and dose-dependent manner. Treatment of cells with equol for 72 h (MDA-MB-231) and 24 h (T47D) was found to inhibit cell growth with IC50 values of 252 μM and 228 μM, respectively. Furthermore, pretreatment of cells with 50 μM equol for 72 h (MDA-MB-231) and 24 h (T47D) sensitized the cells to irradiation. Equol was also found to enhance radiation-induced apoptosis. Comet assay results showed that the radiosensitizing effect of equol was accompanied by increased radiation-induced DNA damages. Conclusions These results suggest for the first time that equol can be considered as a radiosensitizing agent and its effects may be due to increasing cell death following irradiation, increasing the remaining radiation-induced DNA damage and thus reducing the surviving fraction of irradiated cells.